We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Integrated LC-MS System to Be Released in Conjunction with AACC Annual Meeting

By LabMedica International staff writers
Posted on 01 Aug 2016
What may be the first truly integrated sample preparation system for LC-MS (liquid chromatography-mass spectrometry) that allows users to process samples in an instrument that is directly attached to the LC-MS system is to be released at the 2016 AACC Annual Meeting & Clinical Lab Expo (Philadelphia, PA, USA).

Shimadzu Scientific Instruments (Kyoto, Japan) had announced that the release of the Clinical Laboratory Automation Module-2000 (CLAM-2000), a fully integrated sample pretreatment module for LC-MS, will coincide with the 2016 AACC Annual Meeting.

The CLAM-2000 system, which is on display in Booth 4054 of the expo, automatically performs all the processes necessary for analyzing blood and other biological samples, from scanning in information from the blood collection tubes to sample pretreatment and LC-MS analysis. More...
The for-research-use-only instrument is the first truly integrated sample preparation system for LC-MS. It allows users to process samples in an instrument that is directly attached to the LC-MS system, a simple and safe way for lab personnel to process and analyze samples.

The instrument is controlled by a user-friendly interface that offers a variety of functions that regulate reagent management, calibration curve management, control management, and system maintenance management. By automating operations such as dispensing, stirring, filtering, heating, and sample transfer, the system effectively improves data accuracy and achieves the high level of reproducibility needed for clinical research.

“This system highlights the considerable progress made in the use of mass spectrometers for high-sensitivity detection in medical R&D,” said Dr. Scott Kuzdzal, general manager of marketing at Shimadzu Scientific Instruments. “It is ideal for medical research centers, university medical departments, hospital pharmaceutical departments, and contract research organizations that are dealing with issues of variability in analytical results or laboratory efficiency. It can also effectively support forensic applications conducted by universities, research institutes, and testing companies.”

Related Links:
AACC Annual Meeting & Clinical Lab Expo
Shimadzu Scientific Instruments

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.